Abbott Prism Hepatitis B, C And HTLV I/II Assays Gain FDA Panel Nod
This article was originally published in The Gray Sheet
Use of Abbott Laboratories' Prism automated blood screener in conjunction with its hepatitis B surface antigen assay detected an additional 26.3 potentially infectious blood units annually, the company told FDA's Blood Products Advisory Committee Sept 17.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.